Frank Löscher
Algemeen Directeur bij Dermaliq Therapeutics, Inc.
Profiel
Frank Löscher is currently the President & Chief Executive Officer at Dermaliq Therapeutics, Inc. and the Chief Technology Officer at Novaliq GmbH.
He has an undergraduate degree from Ruprecht-Karls-Universität Heidelberg and a doctorate degree from the University of Regensburg.
Actieve functies van Frank Löscher
| Bedrijven | Functie | Begin |
|---|---|---|
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Hoofd Techniek/Wetenschap/O&O | - |
Dermaliq Therapeutics, Inc.
 Dermaliq Therapeutics, Inc. Information Technology ServicesTechnology Services Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical company based in Wilmington, DE, USA. Dermaliq has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital, and Whale Technology Corporation Ltd. The company was founded in 2021 through a spin-off from Novaliq GmbH to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The CEO of the company is Frank Lösher. | Algemeen Directeur | - |
Opleiding van Frank Löscher
| University of Regensburg | Doctorate Degree |
| Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Health Technology |
Dermaliq Therapeutics, Inc.
Dermaliq Therapeutics, Inc. Information Technology ServicesTechnology Services Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical company based in Wilmington, DE, USA. Dermaliq has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital, and Whale Technology Corporation Ltd. The company was founded in 2021 through a spin-off from Novaliq GmbH to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The CEO of the company is Frank Lösher. | Technology Services |
